538 related articles for article (PubMed ID: 19189304)
1. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304
[TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
3. Multifunctional role of VIP in prostate cancer progression in a xenograft model: suppression by curcumin and COX-2 inhibitor NS-398.
Fernández-Martínez AB; Bajo AM; Valdehita A; Isabel Arenas M; Sánchez-Chapado M; Carmena MJ; Prieto JC
Peptides; 2009 Dec; 30(12):2357-64. PubMed ID: 19772879
[TBL] [Abstract][Full Text] [Related]
4. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide (VIP) induces malignant transformation of the human prostate epithelial cell line RWPE-1.
Fernández-Martínez AB; Bajo AM; Isabel Arenas M; Sánchez-Chapado M; Prieto JC; Carmena MJ
Cancer Lett; 2010 Dec; 299(1):11-21. PubMed ID: 20709445
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
7. [Expression and significance of the matrix metalloproteinase inhibitor RECK gene in prostate cell strains].
Xu ZY; Gao JP; Zhang ZP; Ge JP; Xu CL; Sun YH
Zhonghua Nan Ke Xue; 2005 Oct; 11(10):727-30. PubMed ID: 16281502
[TBL] [Abstract][Full Text] [Related]
8. Areca nut extract represses migration and differentiation while activating matrix metalloproteinase-9 of normal gingival epithelial cells.
Tseng YH; Chang KW; Liu CJ; Lin CY; Yang SC; Lin SC
J Periodontal Res; 2008 Oct; 43(5):490-9. PubMed ID: 18624942
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
10. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2: mechanism and regulation of NF-kappaB-mediated activation and its role in cell motility and ECM-invasion.
Philip S; Bulbule A; Kundu GC
Glycoconj J; 2004; 21(8-9):429-41. PubMed ID: 15750784
[TBL] [Abstract][Full Text] [Related]
12. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors.
Wilson SR; Gallagher S; Warpeha K; Hawthorne SJ
Prostate; 2004 Jul; 60(2):168-74. PubMed ID: 15162383
[TBL] [Abstract][Full Text] [Related]
13. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells.
Wang L; Alcon A; Yuan H; Ho J; Li QJ; Martins-Green M
Integr Biol (Camb); 2011 Jul; 3(7):742-54. PubMed ID: 21594291
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
15. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.
Jiang J; Sugimoto Y; Liu S; Chang HL; Park KY; Kulp SK; Lin YC
Anticancer Res; 2004; 24(1):91-100. PubMed ID: 15015581
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional role of CCR9 in prostate cancer cell migration and invasion.
Singh S; Singh UP; Stiles JK; Grizzle WE; Lillard JW
Clin Cancer Res; 2004 Dec; 10(24):8743-50. PubMed ID: 15623660
[TBL] [Abstract][Full Text] [Related]
17. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
18. Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.
Daja MM; Niu X; Zhao Z; Brown JM; Russell PJ
Prostate Cancer Prostatic Dis; 2003; 6(1):15-26. PubMed ID: 12664060
[TBL] [Abstract][Full Text] [Related]
19. Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness.
Zi X; Guo Y; Simoneau AR; Hope C; Xie J; Holcombe RF; Hoang BH
Cancer Res; 2005 Nov; 65(21):9762-70. PubMed ID: 16266997
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: inhibition of proliferation, adhesion, and motility.
Massoner P; Colleselli D; Matscheski A; Pircher H; Geley S; Jansen Dürr P; Klocker H
Endocr Relat Cancer; 2009 Sep; 16(3):795-808. PubMed ID: 19509068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
